# Concurrent nanotherapeutics and regulatory updates for the management of amyotrophic lateral sclerosis: a focused review for orphan drug (Tofersen)

## TL;DR

This review discusses recent developments in ALS treatment, focusing on Tofersen, a new gene therapy, and the potential of nanotherapeutics.

## Contribution

The paper bridges current ALS treatment with future therapies by integrating regulatory updates and nanotherapeutic research.

## Key findings

- Tofersen is the first FDA-approved gene therapy targeting SOD1 mutation-related ALS.
- The review identifies gaps in nanotherapeutics for ALS and suggests future research directions.
- Clinical trials and pharmacovigilance data support Tofersen's safety and efficacy.

## Abstract

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder affecting nerve cells in the brain and spinal cord. With a global incidence of 1.9 to 6 per 100,000 people, ALS is slightly more common in men and prevalent in individuals over 60. However, this review provides a concise update on the regulatory landscape and therapeutic advancements in managing ALS, focusing on the recent approval of Tofersen, the first gene therapy specifically targeting SOD1 mutation-related ALS.

It highlights Tofersen unique role as an orphan drug approved by the US FDA, emphasizing its mechanism of action, gene silencing and its impact on reducing neurodegeneration. Additionally, the review synthesizes data from ongoing clinical trials, pharmacovigilance reports, and case studies to comprehensively understand Tofersen’s safety, efficacy and market exclusivity. Beyond this, it explores the emerging potential of nanotherapeutic approaches to ALS treatment, identifying critical research gaps and future directions.

Integrating regulatory updates, clinical evidence, and innovative therapeutic strategies, the review uniquely contributes to the ALS literature by bridging current treatment realities with potential future therapies, aiming to inform researchers, clinicians, and policymakers on optimizing ALS management.

This review provides a concurrent approach to nanotherapeutics and updates clinical trials for the therapeutic management of amyotrophic lateral sclerosis (ALS).It offers the latest regulatory updates on Tofersen, which is categorised as an orphan drug.The review also provides comprehensive information on the disease pathophysiology of ALS, single-cell molecular dynamics, case study reports, clinical trials, the physicochemical profile, and the regulatory status of Tofersen.Furthermore, it highlights major gaps in current nanotherapeutics approaches, offering valuable insights for future research.

This review provides a concurrent approach to nanotherapeutics and updates clinical trials for the therapeutic management of amyotrophic lateral sclerosis (ALS).

It offers the latest regulatory updates on Tofersen, which is categorised as an orphan drug.

The review also provides comprehensive information on the disease pathophysiology of ALS, single-cell molecular dynamics, case study reports, clinical trials, the physicochemical profile, and the regulatory status of Tofersen.

Furthermore, it highlights major gaps in current nanotherapeutics approaches, offering valuable insights for future research.